Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Clinical trial NCT05038735 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05038735
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-17
- Primary completion
- 2027-01-28
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.